Aradigm Corp. (NSDQ:ARDM) announced last week that it’s officially declaring bankruptcy. Strapped for cash, the Calif.-based company resigned to filing for Chapter 11 protection after it couldn’t confirm funding from its primary investor and partner, Grifols. “Aradigm intends to commence a process to sell substantially all of its assets to an interested party, subject to Bankruptcy […]
FDA wants more clinical data for Aradigm’s inhaled lung drug
Aradigm Corp. (NSDQ:ARDM) shares tumbled today after the company reported that the FDA denied its application for an inhaled drug designed to treat non-cystic fibrosis bronchiectasis patients with chronic lung infections. The agency’s complete response letter reportedly highlighted an array of concerns with the initial application, including product quality and the company’s clinical data. Specifically, the […]
Aradigm lands NIH grant for inhaled, liposomal products
Aradigm Corp. (NSDQ:ARDM) said today that the National Institute of Allergy and Infectious Diseases and the NIH awarded the company a grant to study the treatment of pulmonary non-tuberculous mycobacteria infections with Aradigm’s inhaled liposomal ciprofloxacin products, Linhaliq and Lipoquin. The two-year grant is worth approximately $972,000, according to the Hayward, Calif.-based company. The Phase II […]
Late-stage trial fails for Aradigm’s inhaled antibiotic
Aradigm Corp. (NSDQ:ARDM) said today that its inhaled antibiotic failed in a late-stage clinical trial, sending the Hayward, Calif.-based company’s stock down -54% in premarket trading. Pulmaquin is a once-daily formulation containing ciprofloxacin, a widely prescribed broad-spectrum antibiotic. The inhaled drug was being tested to treat patients with non-cystic fibrosis bronchiectasis (non-CF BE) who have chronic […]
